Inflammatory bowel disease (IBD) is
an immune-mediated disease in which the body’s own immune system attacks the
parts of the digestive system of the human body. Such disease involves
inflammation of lower gastrointestinal tract and causes irreversible damage to
the bowel. Ulcerative colitis and Crohn’s disease are the two major forms of
IBD; both having distinct pathologic and clinical characteristics. IBD is a
difficult to manage medical condition with a higher morbidity rate and thus its
diagnosis and management is of utmost importance.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/inflammatory-bowel-disease-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
The global inflammatory bowel
disease market is categorized as follows:
Application
- Therapeutic
- Diagnostic
Diseased condition
- Crohns disease
- Ulcerative colitis
Product type
- Aminosalicylates
- Antibiotics
- Corticosteroids
- Biologic therapies (biological drugs)
- Immunomodulators
Currently, the developed global
markets of North America and Europe make up for the majority of the
inflammatory bowel disease market in the world. Emerging markets of Asia mainly
India, Russia and Japan as well as countries of Middle East and Latin America
are also expected to show strong growth due to rising incidences of such
diseases owing to increased industrialization, modernization of the population
and drastic lifestyle changes.
One of the key factors driving the
growth of this market is the increase in use of biological therapies such as
monoclonal antibodies. However, difficulties involved in affording the
expensive treatments of such diseases may pose challenge to growth of
inflammatory bowel diseases market majorly in developing nations.
Some of the key players in this
industry are Abbott Laboratories, Amgen, Inc., Bristol-Myers Squibb Company,
Alcon, Inc., Baxter International, Inc., Johnson & Johnson, Sequella, Inc.,
Sanofi-Aventis LLC, Osiris Therapeutics, Inc., AstraZeneca PLC, Eisai Co. Ltd.,
Cephalon, Inc., Celltrion, Inc., Pfizer, Inc., Pluristem Therapeutics, Inc.,
Soligenix, Inc. and Ore Pharmaceuticals, Inc.
This research report analyzes this
market depending on its market segments, major geographies, and current market
trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This report provides comprehensive
analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of
current trends in the market, industry growth drivers, and restraints. It
provides market projections for the coming years. It includes analysis of
recent developments in technology, Porter’s five force model analysis and
detailed profiles of top industry players. The report also includes a review of
micro and macro factors essential for the existing market players and new
entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a technological growth map over time to understand the industry growth rate
- It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
No comments:
Post a Comment